Generic Medicine Info
May be taken with or without food.
Ischaemic heart disease, signs or symptoms of ischaemic coronary artery disease (CAD) or ischaemic heart disease (e.g. angina pectoris of any type, silent myocardial ischaemia, previous MI), coronary artery vasospasm including Prinzmetal's angina, history of cerebrovascular syndromes (e.g. CVA, TIA), peripheral vascular disease (e.g. ischaemic bowel disease), moderate and severe hypertension, uncontrolled hypertension, Wolff-Parkinson-White syndrome or arrhythmias associated with cardiac accessory conduction pathway disorders; history of hemiplegic or basilar migraine, ophthalmoplegic migraine. Severe hepatic impairment. Concurrent use of sumatriptan with or within 24 hours of taking ergotamine, ergotamine derivatives and other 5-HT1 agonists. Concomitant use with or within 2 weeks of discontinuing MAO type A inhibitors.
Special Precautions
Patient with CV risk factors (e.g. diabetes, strong family history of CAD, controlled hypertension, hypercholesterolaemia, postmenopausal women, males >40 years, obesity, smoking); history of seizure disorder or conditions that lower seizure threshold; previous hypersensitivity to sulfonamides or multiple allergens. Not indicated for prophylaxis of migraine or cluster headache. SC inj: Not for IV administration. Mild to moderate hepatic and renal impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Perform CV evaluation prior to initiation of therapy in patients with multiple CV risk factors. For patients with some CV risk factors who have negative CV evaluation, obtain ECG during 1st dose administration in a medically supervised setting. Monitor headache severity, mental alertness, blood pressure; sign and symptoms of serotonin syndrome (e.g. mental status changes, autonomic instability, neuromuscular changes, gastrointestinal symptoms), angina and sensations of chest pain, tightness or pressure.
Adverse Reactions
Significant: Sensation of heaviness, pressure, pain and tightness in the chest, throat, jaw or neck; peripheral vascular ischaemia, colonic ischaemia (with abdominal pain and bloody diarrhoea), splenic infarction, Raynaud's syndrome; exacerbation of headache or medication overuse headache (frequent/prolonged use). Rarely, hypertensive crisis, seizures. Gastrointestinal disorders: Nausea, vomiting; dysgeusia (intranasal). General disorders and administration site conditions: Injection site reactions (e.g. pain, burning, stinging, swelling, erythema, bruising, bleeding); pain, heat or cold sensation, pressure or tightness; malaise, fatigue. Investigations: Transient increase in blood pressure. Musculoskeletal and connective tissue disorders: Myalgia. Nervous system disorders: Dizziness, drowsiness, paraesthesia, hypoaesthesia. Respiratory, thoracic and mediastinal disorders: Dyspnoea; epistaxis, nasal mucosa or throat discomfort, irritation or burning sensation (intranasal). Vascular disorders: Flushing.
Potentially Fatal: Serious cardiac events (e.g. coronary artery vasospasm, acute MI, transient ischaemia, ventricular tachycardia and fibrillation, cardiac arrest), cerebrovascular events (e.g. cerebral or subarachnoid haemorrhage, stroke), serotonin syndrome, hypersensitivity reactions (e.g. angioedema, anaphylaxis).
CIMS Class
Antimigraine Preparations
ATC Classification
N02CC01 - sumatriptan ; Belongs to the class of selective serotonin (5HT1) agonists preparations. Used to relieve migraine.
Disclaimer: This information is independently developed by CIMS based on sumatriptan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in